Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PPA

This article was originally published in The Tan Sheet

Executive Summary

Hemorrhagic stroke risk is due to abuse of PPA-containing weight loss drugs, not proper use of cough/cold remedies, Michael Ernst and Arthur Hartz, MD/PhD, University of Iowa and William Wolowich, Children's Hospital, Columbus, Ohio, et al., state in letters in April 5 New England Journal of Medicine. "Patients who take [PPA] as a weight-loss aid commonly abuse the drug by taking it in higher-than-recommended doses," Wolowich notes. HSP authors Walter Kernan et al. respond their data showed stroke risk also was linked to proper use of cough/cold OTCs, but acknowledge weight loss doses were higher. NEJM released the HSP's findings last November (1"The Tan Sheet" Nov. 13, 2000, p. 4)

You may also be interested in...



Perrigo PPA Product Withdrawal Costs Could Reach $19 Mil.

FDA's request that drug companies voluntarily withdraw phenylpropanolamine-containing cough/cold remedies and appetite suppressants from the market is expected to have no significant, long-term financial impact on two major private labelers who are now reformulating products.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Topics

UsernamePublicRestriction

Register

LL1132098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel